Can Nivolumab be combined with axitinib?

The specific treatment regimen and dosage of whether to use Nivolumab and Axitinib together should be determined by the doctor based on the patient's specific conditions. When using the combination of nivolumab and axitinib, commonly used to treat advanced renal cell carcinoma (RCC), doctors will evaluate the patient's overall health, tumor characteristics and other factors.

Nivolumab is an immune checkpoint inhibitor that enhances the immune system's ability to attack cancer cells. Axitinib is a targeted therapy drug that reduces the blood supply to tumors by inhibiting angiogenesis. Clinical studies show that the combination of nivolumab and axitinib can significantly extend the survival of patients with advanced RCC, with a median progression-free survival rate after starting third-line therapy after previous targeted therapy (PFS) and overall survival (OS) were 2.76 and 8.71 months respectively, and the objective response rate was 18.2%. However, although axitinib is used as a "late" third-line treatment, its efficacy after nivolumab treatment seems to be better. This combination therapy has been approved by relevant drug regulatory agencies and is widely used in clinical practice.

The original drug nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. The price of each box of 40mg/4ml may be around 4,000 yuan. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.